Good point Csnody....,
The golden rule of thumb procedure, if the cause is undetermined or in the event of FDA re commencement approval on the ptx200, is that of an 'outlier'.
That is, no significant skew effect with an outlier due to omission in data pack.
Hope this helps.
Ann: Clinical Trial Update, page-11
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
